Switching to an alternative ALK-inhibitor after alectinib-induced pneumonitis resulted in resolution of this adverse event
The management of metastatic non-small cell lung cancer (NSCLC) has largely shifted over the past several decades from cytotoxic chemotherapy towards targeted therapy for patients with particular genetic driver mutations, such as epidermal growth factor receptor mutations and the abnormal fusion of...
| 發表在: | Current Problems in Cancer: Case Reports |
|---|---|
| Main Authors: | , , |
| 格式: | Article |
| 語言: | 英语 |
| 出版: |
Elsevier
2020-12-01
|
| 主題: | |
| 在線閱讀: | http://www.sciencedirect.com/science/article/pii/S2666621920300235 |